| Similar Articles |
|---|
 |
The Motley Fool
August 22, 2011
Brian Orelli |
Speedy in Seattle Seattle Genetics gets an early approval of Adcentris.   |
The Motley Fool
October 12, 2010
Brian Orelli |
Clinical Trial Positive! Shares Just Barely A story about expectations. Seattle Genetics is two for two in recent weeks. |
The Motley Fool
September 27, 2010
Brian Orelli |
Now That's What I Call a Drug That Works Seattle Genetics hits a home run -- and then some -- with its cancer drug Brentuximab vedotin. |
The Motley Fool
July 10, 2008
Brian Lawler |
Seattle Genetics Has What Others Want Out-licensing its platform technology could mean big bucks. |
The Motley Fool
March 31, 2011
Brian Orelli |
Better Buy? Seattle Genetics or ImmunoGen Battle of the heat-seeking cellular missiles. |
The Motley Fool
September 14, 2010
Brian Orelli |
This Bad News Could've Been Worse A Seattle Genetics drug fails, but there's more in the pipeline. |
The Motley Fool
July 15, 2011
Brian Orelli |
Seattle Genetics Will Work It Out This isn't the NFL labor negotiations. |
The Motley Fool
February 9, 2007
Brian Lawler |
Picking Up the Pace at Seattle Genetics The cash situation shows the shares of this drug development company could be appealing. |
The Motley Fool
January 6, 2011
Brian Orelli |
$145 Million Down; Billions to Go Seattle Genetics signs up another partner. |
The Motley Fool
December 8, 2010
Brian Orelli |
Winners and Losers at the Hematology Society Meeting The American Society of Hematology annual meeting wrapped up yesterday, and as with pretty much every medical meeting, we've got some winning and losing blood-cancer drugs. |
The Motley Fool
August 20, 2011
Luke Timmerman |
Seattle Genetics Wins FDA Approval of First Drug FDA gives a quick turnaround on the new treatment for lymphomas. |
The Motley Fool
July 12, 2011
Luke Timmerman |
Seattle Genetics' New "Empowered Antibody" Looks Clean in FDA Staff Documents FDA reviews Seattle Genetics' Hodgkin's lymphoma drug. |
The Motley Fool
July 5, 2011
Luke Timmerman |
Seattle Genetics, on the Verge of Going Commercial, Seeks to Keep Its Scientific Soul Expectations are sky-high. |
The Motley Fool
January 10, 2007
Brian Lawler |
Seattle Genetics' Big Deal The small biopharmaceutical firm signed a lucrative collaboration deal with biopharma powerhouse Genentech and shares were up 24% as a result. |
The Motley Fool
July 13, 2011
Brian Orelli |
2 Questions for Seattle Genetics So far the FDA is fairly impressed with Seattle Genetics' lymphompa drug brentuximab vedotin. |
The Motley Fool
October 1, 2008
Brian Orelli |
3 Drugmakers With Multiple Shots on Goal Well-stocked pipelines could kick these drugmakers into super-high gear. |
The Motley Fool
April 2, 2008
Brian Lawler |
Seattle Genetics Bulks Up Its Pipeline Seattle Genetics biopharmaceutical clinical studies are firing on all cylinders. |
The Motley Fool
December 19, 2011
Brian Orelli |
ARIAD's Prolific 2011 The biotech is doing something right. |
The Motley Fool
December 9, 2009
Brian Orelli |
Rising From the ASHes At the Super Bowl of blood cancer, the American Society of Hematology's annual conference, the presentations by drug companies made a few stocks catch on fire, while a couple burned up a little. |
The Motley Fool
May 31, 2011
Brian Orelli |
Profit From This Growing Drug Trend Cancer drugs press on. |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. |
The Motley Fool
July 24, 2009
Brian Orelli |
Juicing Up the Earnings Report How did Celgene turn an earnings release that met analysts' expectations while lowering revenue guidance on one of its drugs into an 18.6% increase in share price yesterday? |
The Motley Fool
November 23, 2011
Brian Orelli |
I Was Wrong About Dendreon But maybe not in the long term. |
The Motley Fool
June 6, 2011
Brian Orelli |
Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market. |
The Motley Fool
April 8, 2011
Brian Orelli |
ImmunoGen's Hot Start ImmunoGen scores some positive data, but were investors expecting less? |
The Motley Fool
May 31, 2011
David Williamson |
Roundtable: The World's Best Biotechs Motley Fool analysts choose these as their favorite biotech stocks: Aeterna Zentaris... Seattle Genetics... BioMarin Pharmaceutical... Amarin... |
The Motley Fool
November 29, 2011
Brian Orelli |
Winners and Losers of Roche's Avastin Woes What the FDA giveth, the FDA can taketh away. |
The Motley Fool
December 8, 2009
Brian Orelli |
Early and Often: A Drug Investor's Dream Celgene has two goals for its multiple myeloma drug, Revlimid: to have patients begin taking it earlier in the progression of their disease, and to have them stay on the drug longer. |
The Motley Fool
January 22, 2008
Brian Lawler |
Seattle Genetics' Fortuitous Timing The drugmaker raises some much-needed cash with a $90 million stock offering. |
The Motley Fool
January 30, 2009
Brian Orelli |
Mark Your Calendars: The Race Is On! In the last couple of weeks, both Schering-Plough and Vertex Pharmaceuticals have announced that their phase 3 hepatitis C drugs trials have finished enrolling patients. |
The Motley Fool
July 14, 2011
Luke Timmerman |
Seattle Genetics Wins Unanimous OK for Lymphoma Drug from FDA Panel An FDA panel of cancer drug experts recommended in a 10-0 vote that the company's drug for Hodgkin's lymphoma should be cleared for sale in the U.S. |
The Motley Fool
July 27, 2011
Alexander Crawford |
Vertex Moving Closer to a Cure for Hepatitis C How do you think the treatment of hepatitis C will evolve? |
The Motley Fool
June 29, 2007
Brian Lawler |
Genentech's All Good The biotech's latest partnership deal is nothing to worry about. Investors, take note. |
The Motley Fool
November 30, 2011
David Williamson |
Health Care's 5 Worst November Flops These stocks had a terrible month. |
The Motley Fool
October 31, 2011
Brian Orelli |
5 One-Drug Wonders Going for No. 2 Here are five drugmakers hoping not to become one-hit wonders: Vertex... Onyx... Momenta... Elan... Dendreon... |
The Motley Fool
January 12, 2005
Charly Travers |
Alzheimer's Drug on the Horizon? Myriad Genetics' innovative technology creates an investment opportunity. |
The Motley Fool
February 24, 2011
Brian Orelli |
Profit From Personalized Medicine Pfizer's drug works well, but consider these companies instead. |
The Motley Fool
April 8, 2011
Brian Orelli |
A Shutdown of Binary Events? A government shutdown will likely stop FDA approvals. |
The Motley Fool
January 24, 2008
Brian Lawler |
Vertex Under the Gun Vertex announces development plans for its lead drug. Investors, take note. |
The Motley Fool
March 1, 2007
Brian Lawler |
Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works. |
The Motley Fool
January 5, 2012
Brian Orelli |
Are These Biotech Drug Launches Back on Track? With the annual health-care conference starting up next week, Dendreon and InterMune announced preliminary fourth-quarter sales today. |
The Motley Fool
September 28, 2011
Brian Orelli |
One Step Closer to an FDA Decision Cell Therapeutics is still risky, though. |
The Motley Fool
December 11, 2008
Brian Orelli |
ASH Wrap-Up: Alphabet Soup and Drugs Let's take a look at the data that came out of the American Society of Hematology meeting regarding pharmaceutical companies' medications for blood diseases. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
October 7, 2008
Brian Orelli |
Results IMPACT Volatility at Dendreon Dendreon almost hits both a 52-week high and a 52-week low on the day it releases results. |
The Motley Fool
February 26, 2011
Brian Orelli |
FDA Applications and a Look Ahead It isn't pretty. |
The Motley Fool
August 11, 2010
Brian Orelli |
Dang! This Drug Is Shining Brighter Vertex illuminates telaprevir's additional benefit in treating hepatitis C patients. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Cancer: On Target Once More Over the past year or two, a handful of Phase III failures, including megablockbusters like Avastin and Sutent in trials for all kinds of common tumors, indicate that targeted therapy is generally a blunt instrument. |
Bio-IT World
May 19, 2004
Barbara Depompa |
Surging in Seattle Laid-back coastal-mountain lifestyle bolsters Northwestern biotech company. |
The Motley Fool
March 27, 2009
Brian Orelli |
Trading Up With the $95 From Genentech Genentech is gone; here's what you should replace it with. |
